



PRIOR AUTHORIZATION REQUEST

Opzelura

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number:	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength:	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for ALL PA requests. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements, MDH transmittals and updates to treatment guidelines.

1 Is the request an INITIAL or CONTINUATION of therapy?

☐ Initial (If checked, go to 7)

☐ Continuation (If checked, go to 2)

2 Is the patient currently receiving the requested medication?

[If no, skip to question 7.]

Yes

No

If you have any
questions, call:
1-888-258-8250

Version 11.2025

PRIOR AUTHORIZATION REQUEST

3	Has the patient been receiving medication samples for the requested medication? [If yes, skip to question 7.]	Yes	No
4	Does the patient have a previously approved prior authorization (PA) on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 7.]	Yes	No
5	Has the patient been established on therapy for AT LEAST 3 months? [If no, skip to question 7.]	Yes	No
6	Has the patient experienced a clinically significant benefit from the medication, as documented by the prescriber? [Note: Examples of a response to the requested medication for atopic dermatitis are marked improvements in erythema, induration/papulation/edema, excoriations, and lichenification; reduced pruritus; decreased requirement for other topical or systemic therapies; reduced body surface area affected with atopic dermatitis; or other responses observed.] [No further questions.]	Yes	No
7	What is the indication or diagnosis? ☐ Atopic dermatitis (If checked, go to 8) ☐ Nonsegmental Vitiligo (If checked, no further questions) ☐ Other (If checked, no further questions)		
8	Is the patient greater than or equal to 2 years of age? [If no, no further questions.]	Yes	No
9	Does the patient have a documented diagnosis of mild to moderate atopic dermatitis? [If no, no further questions.]	Yes	No
10	Is the requested medication being prescribed by or in consultation with an allergist, immunologist, or dermatologist? [If no, no further questions.]	Yes	No
11	Does the patient have atopic dermatitis involvement estimated to be 3% to 20% of the body surface area (BSA) according to the prescriber? [If no, no further questions.]	Yes	No
12	Has the patient tried at least TWO medium-, medium-high, high-, and/or super-high-potency prescription topical corticosteroids? [If no, no further questions.]	Yes	No

**If you have any
 questions, call:
 1-888-258-8250**

Version 11.2025



PRIOR AUTHORIZATION REQUEST

13	Was inadequate efficacy demonstrated with the topical corticosteroid therapy, according to the prescriber? [If no, no further questions.]	Yes	No
14	Has the patient tried a topical calcineurin inhibitor (pimecrolimus or tacrolimus) for at least 28 consecutive days? [If no, no further questions.]	Yes	No
15	Was inadequate efficacy demonstrated with the topical calcineurin inhibitor (pimecrolimus or tacrolimus), according to the prescriber? [If no, no further questions.]	Yes	No
16	Has the patient tried Zoryve for at least 4 weeks? [If no, no further questions.]	Yes	No
17	Was inadequate efficacy demonstrated with Zoryve, according to the prescriber? [If no, no further questions.]	Yes	No
18	Does the dose of the requested medication exceed the Food and Drug Administration (FDA) approved labeled dosing for the indication (Dosing: a thin layer applied topically twice daily to affected areas of up to 20% body surface area)?	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

**If you have any
questions, call:
1-888-258-8250**

Version 11.2025